Kin­nate jumps on­to the biotech stage with $74.5M and a fledg­ling can­cer drug pipeline

Can­cer con­tin­ues to be the dis­ease cat­e­go­ry of choice among a large swath of biotech VCs.

San Diego-based Kin­nate has jumped out from the shad­ows …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.